-
Oct 24 |
Diagnostics World | Modern healthcare algorithms are trained with large volumes of data and can recognize patterns and correlate them with outcomes. However, there is still the issue of bias against underrepresented groups, even though these algorithms are trained using diverse populations. Researchers from the Icahn School of Medicine at Mount Sinai have developed AEquity, a tool of identification that reduces biases in datasets used to train machine learning (ML) algorithms.
More
-
Oct 22 |
Diagnostics World | Earlier this month, MyHeritage announced that they have upgraded their at-home DNA tests to have Whole Genome Sequencing. By utilizing Ultima Genomics’ sequencing technology and processing at the Gene by Gene lab, MyHeritage is the first major commercial DNA testing company to adopt Whole Genome Sequencing at such a massive scale of over one million tests per year.
More
-
Oct 16 |
Diagnostics World | A new diagnostic tool could soon help oncologists identify which tumors are most vulnerable to a class of immunotherapies that target cancer’s sugar-coated surface. Researchers at the UC Irvine School of Medicine have developed a companion diagnostic that measures glycan density in tumor tissue, which could redefine how solid tumors are detected, classified, and treated.
More
-
Oct 15 |
Diagnostics World | An innovative GPT model trained on vast amounts of anonymized data from healthy volunteers in the UK Biobank has been shown to be impressively good at predicting an individual’s risk of developing over 1,200 diseases over the next decade. Since the model represents disease risks as rates, it can also quantify how quickly new cases occur within a population over time.
More
-
Oct 14 |
Diagnostics World | As people with rheumatoid arthritis (RA) well know, it is a “forever disease” with no single magic-bullet cure or guarantee that they will ever feel like they did before their diagnosis. But a better understanding of what’s happening biologically before the first swollen joint appears could reveal opportunities to markedly modify the course of RA and, ultimately, prevent it.
More
-
Oct 10 |
Diagnostics World | There are more cases of cancer in the U.S. than ever before. Over 2 million new cases are expected to be diagnosed in 2025 alone, and cancer incidence is on the rise in 6 of the 10 most common cancers. Delivering speedy, accurate diagnoses and treatment for a growing pool of cancer patients is a daunting challenge for today’s clinicians.
More
-
Oct 01 |
Diagnostics World | We have entered a new era of science focused on developing tools and technologies to support early detection and diagnosis. The rapid evolution of research has led to the need to systematically collect, review, and distill findings into clear and actionable recommendations for how to use these tools in clinical practice
More
-
Sep 30 |
Diagnostics World | For patients with metastatic brain cancer, stereotactic radiosurgery has become an increasingly common treatment over the past decade based on the recommendations of medical physicists, guidelines of professional societies, and coverage guidelines of federal agencies. There has also been a change in the drugs used to treat the underlying cancer in conjunction with the procedure, especially in cases of metastatic cancer.
More
-
Sep 25 |
Diagnostics World | GE HealthCare enters an agreement to acquire icometrix; Beckman Coulter Diagnostics launches the industry's first fully automated brain-derived Tau (BD-Tau) research use only (RUO) immunoassay test; and more.
More
-
Sep 24 |
Diagnostics World | Mercy BioAnalytics will commercialize their blood-based ovarian cancer test portfolio; Cyted Health will accelerate the commercial expansion of their diagnostics platform in the U.S.; and more.
More
-
Oct 23 |
Recognized for Global Precision Health Informatics Industry Excellence in Best Practices
More
-
Oct 23 |
More
-
Oct 22 |
More
-
Oct 21 |
Creative Diagnostics introduces a comprehensive suite of validated Inorganic Pyrophosphatase ELISA Kits for the research community.
More
-
Oct 21 |
STEMart announces the launch of its Bacterial Reverse Mutation Test (Ames) service.
More
-
Oct 17 |
Collaboration unites elluminate platform technology and ZS RBQM expertise to offer a fully integrated, data-driven approach to risk and quality management
More
-
Oct 16 |
Proscia®, a pathology AI company, will add AI biomarker detection for skin tissue to its Concentriq® software platform, empowering pathologists to drive efficiency and precision. Powered by Primaa, Cleo Skin* will strengthen Concentriq's lead in offering the industry’s broadest portfolio of AI solutions on a single platform.
More
-
Oct 16 |
Baylor Genetics Presents New Data on Clinical and Diagnostic Utility of RNA Sequencing for Rare Disease at the American Society of Human Genetics 2025 Annual Meeting
More
-
Oct 10 |
Scanogen Inc., a Maryland-based molecular diagnostics company, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its rapid assay for bloodstream infection pathogen identification. The company’s SMART platform delivers species-level results in just two hours—compared to several days with current blood culture methods—enabling earlier, targeted antimicrobial therapy that can improve sepsis outcomes and reduce healthcare costs. Supported by multiple NIH research grants, Scanogen is now raising a Series A financing round to fund pivotal clinical studies and bring this transformative technology to market.
More
-
Oct 08 |
Gifthealth, the patient access solution that unifies the prescription journey from provider to patient, today announced it has now served more than six million patients through its direct-to-patient (DTP) platform.
More
View more articles